Meda, Valeant Pharmaceuticals sales and marketing update
This quarter, Meda and Valeant will terminate their joint commercialization ventures in Canada, Mexico and Australia. Meda said the companies can in the longer term "better explore opportunities" in the markets as separate entities. Valeant returned to Meda product rights to pain drugs flupirtine and Onsolis fentanyl buccal soluble film; and insomnia drug Sublinox zolpidem. Meda will grant Valeant a license for Sublinox in Canada once the JV in Canada is terminated.
Onsolis is an adhesive disc formulation of fentanyl. Sublinox is a sublingual, mucoadhesive zolpidem tablet. Flupirtine, an NMDA receptor antagonist and potassium (K) channel modulator, has been marketed in Europe to treat pain since 1981 (see BioCentury, Aug. 11, 2008). ...